Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief.

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...

Herceptin sales dropped a third in the first nine months of the year due in part to the pandemic but mainly the impact of low-cost biosimilars, although Perjeta remains in-patent for the next few ...

NICE says that there is some evidence that adding Perjeta to standard adjuvant treatment with Roche’s older HER2 drug Herceptin (trastuzumab) or a biosimilar and chemotherapy reduces the risk of ...